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Background. Hyperprolactinemia is frequent in patients with schizophrenic psychoses. It is usually regarded as
an adverse effect of antipsychotics but has recently also been shown in patients without antipsychotic medication.
Our objective was to test whether hyperprolactinemia occurs in antipsychotic-naive ﬁrst-episode patients (FEPs).
Method. In the framework of the European First Episode Schizophrenia Trial (EUFEST), 249 out of 498 FEPs were
eligible for this study, of whom 74 were antipsychotic naive. All patients were investigated regarding their serum
prolactin levels with immunoassays standardized against the 3rd International Reference Standard 84/500.
Results. Twenty-nine (39%) of the 74 antipsychotic-naive patients showed hyperprolactinemia not explained by any
other reason, 11 (50%) of 22 women and 18 (35%) of 52 men.
Conclusions.Hyperprolactinemia may be present in patients with schizophrenic psychoses independent of antipsychotic
medication. It might be stress induced. As enhanced prolactin can increase dopamine release through a feedback
mechanism, this could contribute to explaining how stress can trigger the outbreak of psychosis.
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Introduction
Hyperprolactinemia is frequently found in patients
with schizophrenic psychoses and is usually considered
to be an adverse effect of antipsychotic medication.
It occurs with most conventional antipsychotics
but also during treatment with some new-generation
antipsychotics and is mainly associated with D2 re-
ceptor afﬁnity (Bushe et al. 2008; Fitzgerald & Dinan,
2008; Riecher-Rössler et al. 2009). However, there
have also been recent reports on hyperprolactinemia
in antipsychotic-free patients with ﬁrst-episode psy-
chosis (Kahn et al. 2008; Aston et al. 2010; Garcia-Rizo
et al. 2012) and in patients with an at-risk mental state
(ARMS) for psychosis (Aston et al. 2010).
Prolactin is a peptide hormone secreted mainly
by prolactin-producing cells of the anterior pituitary.
Its main function is to induce lactation. The control
of prolactin production and secretion is complex
(Fig. 1). The main regulatory mechanism is inhibition
by dopamine, which is synthesized in neurons of
the hypothalamus and then secreted through portal
blood into the anterior pituitary, where it exerts
its actions on prolactin-producing cells through D2
receptors. Dopamine is thus the main prolactin-
inhibiting factor (PIF) (Fitzgerald & Dinan, 2008;
Low, 2008; Prabhakar & Davis, 2008). Dopamine toni-
cally inhibits prolactin release. A negative feedback
control of prolactin secretion is mediated by a short
loop mechanism to the hypothalamus. Prolactin acti-
vates prolactin receptors leading to increased dopa-
mine synthesis and release (Fitzgerald & Dinan, 2008;
Low, 2008).
Prolactin secretion is stimulated by sucking but
also by stress (Low, 2008; Prabhakar & Davis, 2008).
Prolactin-releasing factors (PRFs) probably include
thyrotropin-releasing hormone (TRH), vasoactive
intestinal polypeptide (VIP) and oxytocin. Estrogens
also stimulate prolactin synthesis through a positive
feedback loop, and indirectly through their anti-
dopaminergic properties (Low, 2008).
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Hyperprolactinemia (i.e. prolactin serum values
above the normal range) can be caused by many
physiological processes, by psychological distress (for
review see Low, 2008; Prabhakar & Davis, 2008), and
also by pathological conditions such as prolactin-
secreting tumors. Thus, hyperprolactinemia in patients
with schizophrenic psychoses may not only be treat-
ment related but also possibly disease related.
Hyperprolactinemia can suppress gonadal func-
tion with a reduced physiological production of
estrogens and testosterone (Dickson et al. 2000;
Prabhakar & Davis, 2008). This can have serious clinical
consequences (e.g. sexual dysfunction, infertility or
osteopenia) in both men and women (for review see
(Haddad & Wieck, 2004; Miller, 2004; Prabhakar &
Davis, 2008; Riecher-Rössler et al. 2009).
We therefore aimed to determine, in the framework
of the European First Episode Schizophrenia Trial
(EUFEST; Fleischhacker et al. 2005; Kahn et al. 2008),
whether antipsychotic-naive ﬁrst-episode patients
(FEPs) show hyperprolactinemia and, if so, whether
it is associated with factors such as pretreatment, age,
gender or severity of illness. To our knowledge this
is one of the largest samples of antipsychotic-naive
ﬁrst-episode psychosis patients studied regarding
these issues.
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Fig. 1. Control of prolactin (PRL) production and secretion. PRF, prolactin-releasing factor; TRH, thyrotropin-releasing
hormone; VIP, vasoactive intestinal polypeptide; GABA, γ-aminobutyric acid; CNS, central nervous system. Reproduced,
with permission from Elsevier, from W. J. Low (2008). Neuroendocrinology. In Williams Textbook of Endocrinology
(ed. H. M. Kronenberg, S. Melmed, K. S. Polonsky and P. R. Larsen), 9th edn, pp. 85–295. W.B. Saunders Co.:
Philadelphia, PA.
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Method
Data were obtained as part of the EUFEST, the meth-
odology of which has been described in more detail
in previous publications (Fleischhacker et al. 2005;
Kahn et al. 2008). A total of 50 centers participated.
Eligible patients were aged 18–40 years and met
DSM-IV criteria for schizophrenia, schizophreniform
disorder or schizo-affective disorder. Onset of positive
symptoms had to have occurred no more than 2 years
before study entry, and no more than 6 weeks of
lifetime exposure to antipsychotics was allowed.
After complete description of the study to the subjects,
written informed consent was obtained. The trial
complied with the Declaration of Helsinki, and was
approved by the ethics committees of the participating
centers. The Julius Center for Health Sciences and
Primary Care monitored the trial according to Good
Clinical Practice and International Conference on
Harmonisation guidelines.
We included 249 patients from the EUFEST sample
(total 498 patients) in the current study. The remaining
249 patients were excluded for the following reasons:
in 222 it could not be safely conﬁrmed that they had
had their blood samples for prolactin drawn before
having received their ﬁrst antipsychotic medication,
21 had unknown previous medications apart from
antipsychotics, and six were non-Caucasian. The latter
were excluded as there is some evidence that there
might be ethnic differences regarding the hormonal
response to psychological stressors (Chong et al. 2008).
Baseline data included demographics, diagnosis,
treatment setting, psychopathology [Positive and
Negative Syndrome Scale (PANSS); Kay et al. 1987],
severity of illness [Clinical Global Impressions (CGI)
scale; Guy, 1976], and other parameters described
in the original papers. Pretreatment history was ascer-
tained by questioning patients and signiﬁcant others,
in addition to reviewing available charts.
Prolactin measurements
In each center, immunoassays were used for prolactin
measurements, which were standardized against
the 3rd International Reference Standard 84/500. The
lower and upper reference limits were calculated as
the 5th and 95th percentiles. Hyperprolactinemia
in this reference is deﬁned as a value above the
95th percentile, that is >0.38 U/l in men and >0.53 U/l
in women. To convert values from ng/ml to U/l we
used a conversion factor of 0.0212 (Kahn et al. 2008).
Statistical methods
The R environment for statistical computation was
used to analyze the EUFEST dataset (R Development
Core Team, 2011). Simple parametric and non-
parametric statistical tests, such as the Mann–Whitney
U test and the Student t test, were performed to analyze
group differences. χ2 tests and Fisher’s exact tests were
applied wherever count data were analyzed.
Log-transformed prolactin values were modeled
by age, sex and PANSS positive/negative score to
account for the inﬂuence of relevant variables. A gen-
eralized linear model (GLM) approach was adopted,
speciﬁed by a log link function and gamma family dis-
tribution. As the mean function indicates a squared
relationship between mean log prolactin and its stan-
dard deviation, the assumption of an exponential
residual distribution seems to be justiﬁed and hence
the choice of a GLM belonging to the gamma family.
An analysis of deviance was performed to determine
a particular factor’s contribution in explaining pro-
lactin deviance [a concept functional equivalent to
variance in ordinary least squares analysis but speciﬁc
to GLMs and other modern approaches in linear
modeling].
Results
Of the 249 FEP patients with reliable records on medi-
cation before prolactin measurements, 74 (52 men
and 22 women) were naive for the intake of any anti-
psychotic medication. Clinical and demographic char-
acteristics of the 74 antipsychotic-naive and the 175
not-naive patients are summarized in Table 1.
Hyperprolactinemia in antipsychotic-naive patients
As expected, a high proportion of the patients
with prior or current intake of antipsychotics showed
hyperprolactinemia (i.e. levels above the upper limit
of the normal range). However, 30 (40.5%) of the 74
antipsychotic-naive patients also showed hyperprolac-
tinemia: 11 (50%) of the 22 women and 19 (36.5%) of
the 52 men.
The mean prolactin values were also strongly
elevated not only in the non-naive but also in the
antipsychotic-naive patients, and the elevation was
especially high in women. Table 2 shows the pro-
portion of patients with hyperprolactinemia in both
groups according to gender, along with the mean pro-
lactin values.
For further analyses, unless stated otherwise, we
focused on the antipsychotic-naive sample.
Inﬂuence of other previous medications
Of the 30 antipsychotic-naive patients with hyper-
prolactinemia, 20 had taken some other medication:
benzodiazepines (n=13), biperiden (n=3), pridinol
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(n=2), hydroxyzine (n=1), propanolol (n=1), meto-
clopramide (n=1), cetirizine (n=1), omeprazol (n=1)
and sulfacetamide (n=1). None of the antipsychotic-
naive women had taken oral contraceptives. There
was no signiﬁcant difference in prolactin values be-
tween the 20 patients with previous medication
(mean 1.22±0.86 U/l) and the 10 who were completely
medication naive (mean 0.70±0.30 U/l, Mann–Whitney
U=64, p=0.118). Only one of these patients had taken
drugs known to increase prolactin (metoclopramide
and omeprazol). For further analyses we excluded
this patient. We were thus left with 29 out of 74
(39.2%) FEP patients whose hyperprolactinemia could
not be explained by antipsychotics or any other
medication.
Inﬂuence of age and gender
There was no signiﬁcant age difference between the 29
antipsychotic-naive patients with unexplained hyper-
prolactinemia (mean age 25.1±5.4 years) and the 44
antipsychotic-naive with normal prolactin values
(mean age 26.2±5.7 years) (t=0.8, df=72, p=0.412),
but there were signiﬁcant gender differences. Anti-
psychotic-naive women had higher prolactin values
than men, and the range of values was much larger
in the female patients (Fig. 2).
Inﬂuence of symptomatology
We also tested whether hyperprolactinemia was
associated with the severity of psychopathological
Table 1. Sociodemographic and clinical characteristics of antipsychotic-naive versus non-naive ﬁrst-episode patients (FEPs)
Antipsychotic naive
(n=74)
Antipsychotic non-naive
(n=175)
Total
(n=249) p
Men/women, n (%) 52 (70)/22 (30) 105 (60)/70 (40) 157 (63)/92 (37) 0.151a
Age (years), mean±S.D. 25.8±2.8 26.0±5.5 25.9±5.5 0.739b
Years of education, mean±S.D. 12.8±2.8 12.6±3.1 12.7±3.0 0.376b
Diagnosis, n
Schizophrenic psychosis 46 84 30
Schizo-affective psychosis 6 15 21 0.106c
Schizophreniform disorders 22 76 98
S.D., Standard deviation.
a Fisher’s exact test for count data.
bMann–Whitney U test for ranked data.
c χ2 test for contingency tables.
Table 2. Hyperprolactinemia and prolactin values of antipsychotic-naive versus non-naive patients with ﬁrst-episode psychosis
Antipsychotic naive Antipsychotic non-naive
Men
(n=52)
Women
(n=22)
Total
(n=74)
Men
(n=105)
Women
(n=70)
Total
(n=175)
Proportion of patients with
hyperprolactinemiaa, n (%)
19 (36.5) 11 (50.0) 30 (40.5) 75 (71.4) 52 (74.3) 127 (72.6)
Prolactin (U/l) blood levels
Mean±S.D. 0.37±0.32 0.98±0.94 0.55±0.64 0.83±0.91 1.60±1.44 1.14±1.21
Median 0.26 0.58 0.34 0.68 1.16 0.80
Range 0.04–1.50 0.11–3.29 0.04–3.29 0.00–8.58 0.10–6.66 0.00–8.58
Men versus women
Mann–Whitney U test 850.5 4956.0
p value <0.001 <0.001
S.D., Standard deviation.
a Normal values: men<0.38 U/l; women<0.53 U/l.
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symptoms and/or diagnostic subtype in antipsychotic-
naive patients. Table 3 shows the different PANSS
and CGI scores and also speciﬁc diagnoses for all
antipsychotic-naive patients, comparing the groups
with and without unexplained hyperprolactinemia.
There was no diagnostic subtype disproportionately
more frequently affected by hyperprolactinemia.
Patients with hyperprolactinemia did not differ from
patients without hyperprolactinemia in terms of the
severity of psychopathological symptoms. Further-
more, there was no correlation of log prolactin
values with the total CGI score (Spearman’s ρ=0.02,
p=0.850), the PANSS positive score (r=0.04, t72=0.31,
p=0.756) or the PANSS negative score (r=0.11, t72=
0.95, p=0.345). Additionally, we tested the correlation
with the anxio-depressive dimension of the PANSS
according to El Yazaji et al. (2002), and this was also
not signiﬁcant (r=0.04, t72 =0.30, p=0.763).
GLM
In a next step we analyzed the factors potentially
inﬂuencing prolactin levels, such as sex, age and
severity of psychopathology, that is PANSS positive
and negative scores, within the 73 antipsychotic-naive
patients. Using an analysis of deviance of a GLM, we
entered age, gender and the PANSS positive and nega-
tive scores into the model.
Age and the PANSS positive score did not contrib-
ute to explaining a signiﬁcant amount of variance
of the data. However, there were signiﬁcant main
effects of gender (χ2=24.9, df=1, p<0.001) and the
PANSS negative score (χ2=4.6, df=1, p=0.032), and
an interaction of gender with the PANSS negative
score (χ2=7.9, df=1, p=0.005). The mean prolactin
level in women with an average negative symptom
load (PANSS negative) amounted to 0.98 U/l. By con-
trast, the mean prolactin level in men was only 37%
of the value seen in women. The negative symptoms
(PANSS negative) yielded a differential effect on the
prolactin level depending on gender: whereas an
increasing value of the PANSS negative score was
strongly associated with a decreased prolactin level
in women (–7%/scale unit PANSS negative), a slightly
inverse relationship was found in men (+3%/unit
PANSS negative).
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Fig. 2. Prolactin values of patients with ﬁrst-episode psychosis, naive and not naive for antipsychotics, differentiated by
gender. Log prolactin levels depend on gender and neuroleptic treatment. Dotted lines indicate a gender-speciﬁc cut-off value.
Values above this line represent hyperprolactinemia. The boxes surrounding some of the values comprise all values that fall
within the ﬁrst and third quantiles. The horizontal line that is approximately centered within the box corresponds to the
median of the particular subsample. a After exclusion of one man (see text).
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Clinical sequelae
With regard to potential clinical sequelae of hyper-
prolactinemia, patients were speciﬁcally asked about
galactorrhea or amenorrhea. None of the antipsy-
chotic-naive patients suffered from galactorrhea and
only two of the women had amenorrhea, both in the
group with hyperprolactinemia.
Discussion
We have studied 74 antipsychotic-naive FEPs with
psychosis within the EUFEST study (Fleischhacker
et al. 2005; Kahn et al. 2008). Twenty-nine (39.2%) of
these FEPs showed hyperprolactinemia unexplained
by any medication or other known inﬂuence. To
our knowledge this is one of the largest samples of
antipsychotic-naive FEP patients studied regarding
this issue. Our ﬁndings indicate that hyperpro-
lactinemia in FEP is not necessarily only caused by
antipsychotics, but might also be a pre-existing con-
dition in some patients. This corroborates a previous
ﬁnding from the Basel early-detection-of-psychosis
(FEPSY) study (Aston et al. 2010), in which hyperpro-
lactinemia was found in 33% of all antipsychotic-naive
FEP patients, and even in 24% of antipsychotic-naive
patients with an ARMS for psychosis. Similarly,
Garcia-Rizo et al. (2012) have recently reported
higher prolactin concentrations in 33 newly diagnosed
antipsychotic-naive patients with non-affective psy-
chosis compared to 33 matched controls in a well-
controlled study. Guest et al. (2011) have also reported
elevated prolactin concentrations in the blood of 236
ﬁrst-episode and recent-onset patients with schizo-
phrenic psychoses compared to 230 matched controls.
Patients were antipsychotic naive or antipsychotic
free for at least 6 weeks. Segal et al. (2004) only
found higher prolactin levels in the disorganized sub-
type of schizophrenic psychoses. Their sample con-
sisted of ﬁrst-episode and recurrent patients, both
unmedicated. Meltzer et al. (21) and Kuruvilla et al.
(22) were not able to demonstrate differences in mean
prolactin values between smaller samples of newly ad-
mitted unmedicated schizophrenic psychoses patients
andhealthy controls.However, the prevalence of hyper-
prolactinemia (i.e. the proportion of patients with
levels above the norm) was not reported in their
studies and mean values might not be as informative.
It has previously been suggested that hyperprolacti-
nemia may have been present before the introduction
Table 3. Psychopathological symptoms of antipsychotic-naive ﬁrst-episode patients (FEPs) with and without unexplained
hyperprolactinemia (HP)
No HP (n=44) Unexplained HP (n=29)a Total (n=73)a Statistics
Men/women, n (%) 33 (65)/11 (50) 18 (35)/11 (50) 51 (100)/22 (100) p=0.300
Age (years), mean (S.D.) 26.2 (5.7) 25.3 (5.3) 25.8 (5.6) t71=0.66, p=0.512
b
PANSS, mean (S.D.)
Positive score 20.9 (6.2) 21.0 (5.7) 20.9 (6.2) t71=0.08, p=0.931
b
Negative score 18.6 (8.2) 21.2 (7.1) 21.3 (6.0) t71=1.40, p=0.167
b
Anxio-depressive dimensionc 9.8 (3.4) 9.8 (3.8) 9.8 (3.5) t71=0.09, p=0.931
b
CGI, n (%)
Borderline mentally ill 2 (5) 0 (0) 2 (3) p=0.514d
Mildly ill 1 (2) 2 (7) 3 (4) p=0.559d
Moderately ill 13 (30) 8 (28) 21 (28) p≈1.00d
Markedly ill 23 (52) 14 (48) 38 (51) p=0.813d
Severely ill 5 (11) 5 (17) 10 (14) p=0.505d
Diagnostic subtype, n (%)
Paranoid 22 (50) 17 (59) 39 (53)e p=0.485d
Schizophreniform 15 (34) 7 (24) 22 (30)e p=0.440d
Schizo-affective 3 (7) 3 (10) 6 (8)e p=0.676d
Undifferentiated 4 (9) 2 (7) 6 (8)e p≈1.00d
PANSS, Positive and Negative Symptom Scale; CGI, Clinical Global Impression; S.D., standard deviation.
a One patient with intake of prolactin-increasing medication (metoclopramide and omeprazol) was excluded.
b Two-sample Student’s t test.
c PANSS items G1, G2, G3, G6.
d Fisher’s exact test for count data.
e Percentages do not add up to 100% due to rounding errors.
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of antipsychotics in some patients with schizophrenic
psychoses (Riecher-Rössler & Häfner, 1993; Riecher-
Rössler et al. 1998). Indirect evidence for this stems
from earlier observations of gonadal dysfunction
and hypoestrogenemia in unmedicated patients with
schizophrenic psychoses. Both suppression of gonadal
function and suppression of estrogen production are
well known consequences of hyperprolactinemia and
both have been described as early as at the beginning
of the last century, when antipsychotics had not yet
been developed (for review see Riecher-Rössler
& Häfner, 1993; Riecher-Rössler et al. 1998). Thus,
Kraepelin (1909–1915) and Kretschmer (1921) had
already reported that many women with schizophrenic
psychoses showed physical signs indicating ‘insufﬁ-
cient functioning of the sexual glands’ with ‘hypo-
estrogenism’. In the 1930s, studies analyzing estrogen
levels in blood and urine found decreased estrogen
levels in most in-patients with schizophrenic psychoses
(Riecher-Rössler & Häfner, 1993; Riecher-Rössler et al.
1998). Again, antipsychotics were not available then.
Prolactin levels were not measured in those days.
Our ﬁndings are also in line with recent MRI ﬁnd-
ings that showed an increased pituitary volume in
antipsychotic-free FEP patients and even in patients
with an ARMS for psychosis, especially in those with
a later transition to frank psychosis (Garner et al.
2005; Pariante, 2008; Büschlen et al. 2010; Walter et al.
2012), although there is a recent study at odds with
this (Klomp et al. 2012). As prolactin production in
the pituitary is known to be associated with an enlar-
gement of the gland (MacMaster et al. 2007), this
could theoretically indicate increased prolactin pro-
duction during emerging psychosis.
Potential clinical implications
Our ﬁndings, if conﬁrmed, would have implications
for research and also for clinical practice. Hyperpro-
lactinemia can have many adverse clinical effects
(Riecher-Rössler et al. 2009). Not only can it lead to
galactorrhea, but it can also suppress the activity of
the hypothalamic–pituitary–gonadal (HPG) axis and
gonadal function, leading to a reduced physiological
production of estrogens and testosterone (Dickson
et al. 2000; Prabhakar & Davis, 2008). It may cause
amenorrhea and menstrual irregularities in women
and erectile dysfunction, along with ejaculatory prob-
lems and reduced spermatogenesis, in men. In both
genders it can be associated with emotional lability,
loss of libido, orgasmic dysfunction and infertility
(Haddad & Wieck, 2004; Miller, 2004; Prabhakar &
Davis, 2008; Riecher-Rössler et al. 2009). As was shown
in the total sample of all FEPs of the EUFEST study,
higher prolactin plasma levels predict amenorrhea in
women and erectile and ejaculatory dysfunction in
men (Malik et al. 2011). Chronic hyperprolactinemia
has also been associated with osteopenia and osteo-
porosis (O‘Keane & Meaney, 2005) and an increase in
the risk of bone fracture (Howard et al. 2007), although
exposure to prolactin-increasing antipsychotics in one
study was not found to be related to bone mineral den-
sity (Hummer et al. 2005). Finally, there has been some
discussion about a possible relationship between hyper-
prolactinemia and a slightly increased risk for breast
cancer (Prabhakar & Davis, 2008; Bushe et al. 2009).
Most of the mentioned sequelae of hyperprolactine-
mia are indirect effects caused by the suppression of
gonadal estrogen and testosterone production. Only a
few, such as galactorrhea, are direct effects of hyper-
prolactinemia (Riecher-Rössler et al. 2009). The poten-
tially increased risk of breast cancer is also thought
to be such a direct effect. These direct effects have
mainly been documented in patients with other causes
of high prolactin levels, such as prolactinoma, which
lead to considerably higher levels of plasma prolactin
than those reported here.
From an endocrinological point of view, prolactin
levels should be measured before commencing anti-
psychotic treatment to ensure that hyperprolactinemia
is not a pre-existing condition, which would need
thorough investigation. Blood samples should be
taken in a standardized manner (in the morning be-
tween 08:00 and 10:00 h, without any stressful inﬂu-
ences, etc.). If hyperprolactinemia is found and
deemed not to be drug related, other causes such as
thyroid hypofunction or tumors in the area of the pitu-
itary need to be excluded. Potential adverse clinical
sequelae should be treated if hyperprolactinemia is
persisting and cannot be treated causally.
Potential research implications
Besides potential clinical consequences, our ﬁndings
may also have implications for research. It might be
that, in antipsychotic-naive patients with prodromal
states or ﬁrst-episode psychosis, hyperprolactinemia
is caused by psychological distress associated with
the (emerging) illness. It is well known that stress
can activate not only cortisol but also prolactin
secretion (Low, 2008; Prabhakar & Davis, 2008). The
increased pituitary volumes seen in these patients
might be due not only to an increase in the production
of adrenocorticotropic hormone (ACTH), as suggested
previously (Pariante, 2008), but also to an increase in
the production of prolactin in the pituitary
(MacMaster et al. 2007).
Furthermore, it might be speculated that stress-
induced hyperprolactinemia plays a role in triggering
the outbreak of acute psychotic symptomatology
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because hyperprolactinemia induces the production of
prolactin-inhibiting factor (PIF), which is more or less
identical with dopamine (Low, 2008).
Dopaminergic transmission is well known to be
increased in acutely psychotic patients and even in
people at risk for psychosis (Howes & Kapur, 2009).
Furthermore, stress in such individuals has been linked
to both an increase of symptoms and an increase in
dopaminergic indices (van Winkel et al. 2008; Howes
& Kapur, 2009; van Os et al. 2010; Mizrahi et al.
2012). It is accepted that different forms of stress can
enhance the risk for psychosis and may trigger its out-
break acutely (Phillips et al. 2006; van Winkel et al.
2008; Howes & Kapur, 2009; van Os et al. 2010).
This has been integrated into an ‘advanced’ dopamine
hypothesis as the ﬁnal common pathway for psychosis
(Howes & Kapur, 2009). However, the exact mech-
anisms of how stress inﬂuences dopaminergic neuro-
transmission are not yet completely understood
(Phillips et al. 2006; van Winkel et al. 2008; Howes &
Kapur, 2009; Ungless et al. 2010; van Os et al. 2010).
Ungless et al. (2010), in a review of the effects of
stress on dopamine neurons, state that ‘a major target
of stress, and stress-related hormones in particular,
are fast excitatory and inhibitory synapses made onto
dopamine neurons’. This is where prolactin, which
also serves as a stress hormone, may play a possible
role in the pathogenesis of (emerging) psychosis
as it can directly enhance dopamine levels through a
feedback mechanism (Fitzgerald & Dinan, 2008; Low,
2008) (see Fig. 1). Stress can, among other factors,
induce hyperprolactinemia, which in turn, as a regulat-
ory mechanism to down-regulate prolactin secretion,
induces an increase in PIF (i.e. dopamine). This
increase in dopamine would then be able to trigger
psychotic symptoms in individuals vulnerable for psy-
chosis. This would mean that the tuberoinfundibular
dopamine pathway may be involved in the pathogen-
esis of schizophrenic psychoses, and not just the meso-
limbic and mesocortical pathways as hypothesized
prominently in the literature.
This extension of the stress–dopamine hypothesis
could help to explain the well-known fact that stress
can trigger the outbreak of psychotic symptoms. It
might also help to explain why many patients develop
schizophrenic psychoses during periods of their lives
with strong ﬂuctuations of sex hormones and prolac-
tin, such as during adolescence or, in women, during
the postpartum or perimenopausal period (Häfner
et al. 1993; Riecher-Rössler & Häfner, 1993; Riecher-
Rössler et al. 1994, 1998).
Of note, hyperprolactinemia and also the increase in
the pituitary volume found in our and other studies
(Büschlen et al. 2010) have been demonstrated predo-
minantly in women. At the same time, it has been
shown that women have a stronger prolactin response
to antipsychotics (Yasui-Furukori et al. 2010). Both
ﬁndings might be explained by the fact that estrogens
sensitize the pituitary to release prolactin (Fitzgerald &
Dinan, 2008; Low, 2008). In this context it is also of
interest that men and women react differently to stress
(Kirschbaum et al. 1999).
We could not conﬁrm our hypothesis that prolactin
levels are associated with the severity of positive psy-
chotic symptomatology. However, we did ﬁnd a gen-
der difference regarding negative symptoms. More
negative symptoms were related to lower prolactin
levels in antipsychotic-naive women but to higher
levels in antipsychotic-naive men. These gender differ-
ences are difﬁcult to explain. It is possible that the
intense stress reaction in women with a very high
rise of prolactin is attenuated by negative symptoms
such as affective ﬂattening.
However, our contrasting ﬁnding in men is in ac-
cordance with that of Akhondzadeh et al. (2006), who
found a positive correlation between prolactin plasma
levels and negative subscale scores in male patients
with chronic schizophrenia. At the same time, their
patients had low testosterone levels, which might indi-
cate that hyperprolactinemia-induced suppression
of gonadal function with a decrease in testosterone
production can result in an increase of negative symp-
toms. This might open up new therapeutic options
with adjunctive testosterone in negative symptoms
(Akhondzadeh et al. 2006), similar to the adjunctive
treatment with estrogens for positive symptoms (for
review see Riecher-Rössler & de Geyter, 2007;
Riecher-Rössler & Kulkarni, 2011).
There are also genetic links between prolactin and
schizophrenic psychoses. The prolactin gene has been
mapped to chromosome 6p21 (Evans et al. 1989) and
this region has long been discussed as a susceptibility
locus for schizophrenic psychoses genes (Schwab
et al. 2003; Tochigi et al. 2004; Roig et al. 2007).
Stevens et al. (2001) identiﬁed a functional polymor-
phism –1149 G/T (rs1341239) of the prolactin gene,
where the G allele has been associated with higher pro-
moter activity of the gene and a greater increment of
prolactin mRNA. In a ﬁrst study of this polymorphism,
a signiﬁcant preponderance of this allele was found in
patients with schizophrenic psychoses compared to
healthy controls (Rybakowski et al. 2011). It could
therefore be hypothesized that individuals with a pre-
ponderance of the G allele react more strongly to stress
and thus show a higher risk of psychotic breakdown.
Limitations
We cannot completely rule out the possibility that
some patients who claimed never to have received an
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antipsychotic may have nevertheless been pretreated.
We consider this possibility unlikely given the early
stage of the illness and the fact that we had good
back-up information from relatives and patient re-
cords. Very extensive questioning about previous
medication was a focus of the EUFEST study, so we
can assume that under-reporting was very low. If
there was any doubt, patients were excluded from
the prolactin study. In addition, even if we made erro-
neous assumptions about some patients’ pretreatment
status, it would be difﬁcult to explain our ﬁnding of
a considerable increase in prolactin across the full
sample.
Because prolactin levels were not measured in a
central laboratory but rather in the individual study
centers, there may have been some variation in ab-
solute prolactin level differences. However, as all cen-
ters used immunoassays standardized against the
3rd International Reference Standard 84/500, the
assessment of ‘hyperprolactinemia’ seems correct.
Prolactin secretion follows a circadian and ultradian
rhythm and to a lesser extent depends on the phase of
the menstrual cycle. Although centers were instructed
to collect blood samples in the morning, there was no
control for menstrual cycle-dependent variations in
female patients, which may have contributed to var-
iance in prolactin levels in females. However, apart
from the magnitude of effects, we did ﬁnd increased
prolactin levels in both sexes.
Lastly, given our rigorous exclusion approach, we
were left with a relatively small patient sample
of truly antipsychotic-naive individuals. At the same
time, however, this rigorous approach is a strength
of our study.
Conclusions
Clinically, our ﬁndings indicate that prolactin should
be measured in patients with ﬁrst-episode psychosis
and putative prodromal states before the introduction
of antipsychotics. In terms of research, our ﬁndings
may contribute to explaining how stress may trigger
the outbreak of schizophrenic psychoses: stress induces
hyperprolactinemia that, through feedback, can
increase dopamine. The latter is certainly speculative
but should stimulate further research.
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